Dr. Wong on Anti-Amyloid Fibril Treatments in AL Amyloidosis
February 6th 2018
Sandy Wong, MD, assistant professor, University of California, San Francisco School of Medicine, discusses anti-amyloid fibril treatments, a class of agents that have yet to receive FDA approval in the treatment of patients with immunoglobulin light chain amyloidosis (AL amyloidosis).